生物衰老加速与阿尔茨海默病的血生物标志物水平有关
Jaclyn M Eissman1,2, Yiyi Ma1,2, Min Qiao1,2
1The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 23, 2026
概括
来自西班牙裔成年人血液甲基化数据的生物年龄加速预测了阿尔茨海默病 (AD) 风险,并与AD生物标志物如P-tau217.7相关. 这种基于血液的衰老时钟与临床前阿尔茨海默病检测有关.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 表观遗传钟显示与阿尔茨海默病 (AD) 临床风险和血液生物标志物的混合关联,特别是在非欧洲人群中.
- 了解生物衰老在阿尔茨海默氏症发病过程中的作用,对于开发有效的干预措施至关重要.
研究的目的:
- 调查表观遗传年龄加速与阿尔茨海默病 (AD) 临床风险和老年西班牙裔成年人的血生物标志物之间的关联.
- 为了确定基于血液的表观遗传钟是否可以在临床前队列中分层AD风险.
主要方法:
- 从704名老年西班牙裔成年人的血液DNA甲基化数据计算出生物年龄和年龄加速.
- 测试了与临床AD诊断和死前血生物标志物水平的相关性,包括P-tau217.
- 通过APOE-ε4载体状态分层检查了相关性,并探索了与免疫细胞甲基化之间的关系.
主要成果:
- 年龄加速与性别,临床诊断和八种血生物标志物显著相关,特别是P-tau217.
- 在非载体APOE-ε4中,生物标志物相关性更为显著.
- CD4和CD8T细胞中的甲基化水平与衰老加速有关.
结论:
- 基于血液的生物衰老加速可以在西班牙裔队列中对临床AD风险进行分层,为临床前个体进行了丰富.
- 在血液中测量的生物衰老与血AD生物标志物水平有关,在非携带APOE-ε4的人群中可能特别重要.
- 免疫T细胞的组成与生物衰老有关,这表明免疫功能和AD病变发生之间存在联系.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.年龄加速的加速度.生物衰老 生物衰老基因表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表观表甲基化处理的方法血生物标志物 血生物标志物临床前疾病的临床前疾病风险分层的风险分层.更多相关视频
09:38Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...